← SEC 公告列表 | LKFT SEC 公告 | Lakefront Biotherapeutics（LKFT）

重大事件 外國發行人報告 6-K 2026-06-30

Lakefront Biotherapeutics 6-K 公告股份回購進度，期間買入逾8萬股

於 SEC 網站開啟原文

AI 繁中摘要

美國證券交易委員會（SEC）6-K 申報文件摘要 申報類型：6-K（外國私營發行人報告） 發行人：Lakefront Biotherapeutics NV（代號：LKFT，於 Euronext 及 NASDAQ 雙重上市） 日期：2026 年 6 月 30 日 --- 📢 **股份回購進度更新** Lakefront Biotherapeutics 於 2026 年 6 月 9 日公佈的股份回購計劃持續執行。在 2026 年 6 月 22 日至 26 日期間，公司於 Euronext Amsterdam（XAMS）合共回購 **83,530 股** 普通股，總代價約 **2,108,045 歐元**，平均每股買入價為 **25.24 歐元**，價格區間介乎 24.38 至 25.82 歐元。 截至 2026 年 6 月 26 日收市，公司持有 **199,734 股** 庫存股。 --- 🏢 **公司背景簡介** Lakefront Biotherapeutics（前稱 Galapagos）為一間生物科技公司，專注於開發針對嚴重疾病（尤其高未滿足醫療需求領域）的創新藥物。其臨床階段管線集中於免疫學及炎症，旗艦資產為 **gamgertamig**——一種潛在同類首創的 BCMAxCD3 T 細胞銜接分子，應用於自體免疫疾病。公司具備強勁的交易能力、營運靈活性及穩健資本狀況，透過識別、收購及推進優質資產，致力為患者帶來實質影響及長期股東價值。 --- ⚠️ **前瞻性陳述與風險提示** 本新聞稿包含根據《1995 年私人證券訴訟改革法》定義的前瞻性陳述，涉及已知及未知風險、不確定性及其他因素，可能導致實際結果與預期有重大差異。相關風險詳見公司向 SEC 提交的文件（包括最近期的 20-F 年報及後續申報）。公司明確表示無義務更新任何前瞻性陳述，除非法律或監管要求。 投資者應注意，股份回購計劃並不保證未來股價表現，亦不代表公司對未來業績的預測。建議查閱完整 SEC 申報文件以了解更多細節。
展開英文正文 
EX-99.1
2
exh_991.htm
PRESS RELEASE

EdgarFiling

EXHIBIT 99.1
Acquisition of Own Shares

 Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information
 Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 83,530 Lakefront shares between 22 June 2026 and 26 June 2026, as follows:
 Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
22/06/2026XAMS15,29724.59376,162.4124.3824.96
23/06/2026XAMS15,05025.32381,076.5325.0625.52
24/06/2026XAMS18,94425.55483,992.6825.3025.78
25/06/2026XAMS17,23925.41438,065.4025.1225.72
26/06/2026XAMS17,00025.22428,748.5024.9425.82
Total 83,53025.242,108,045.5224.3825.82
 As of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares.
 About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
 For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1 412 522 [email protected]
 Forward-looking statementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.